<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414947</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2111</org_study_id>
    <nct_id>NCT00414947</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the bioequivalence as well as rate and extent of absorption of&#xD;
      vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. compared to the imported&#xD;
      vildagliptin tablet in Chinese healthy volunteers.&#xD;
&#xD;
      This trial is not recruiting patients in the United States,&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. to imported vildagliptin tablet in Chinese healthy subjects</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of vildagliptin tablet after a 50 mg single dose</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin (LAF237)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese healthy male subjects age 18 to 40 years of age included&#xD;
&#xD;
          -  In good health&#xD;
&#xD;
          -  Male subjects using a double-barrier local contraception for the entire duration of&#xD;
             the study up to study completion visit and refraining from fathering a child in the&#xD;
             three months following last study drug administration.&#xD;
&#xD;
          -  Body mass index within the range of 19 to 24 kg/m2 and weigh at least 50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter&#xD;
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to&#xD;
             dosing. Paracetamol is acceptable.&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing.&#xD;
&#xD;
          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or&#xD;
             longer if required by local regulation.&#xD;
&#xD;
          -  Significant illness within two weeks prior to dosing.&#xD;
&#xD;
          -  A past personal or close family medical history of clinically significant cardiac&#xD;
             abnormalities.&#xD;
&#xD;
          -  History of:&#xD;
&#xD;
               -  Fainting, low blood pressure when standing, irregular heartbeats,&#xD;
&#xD;
               -  Acute or chronic bronchospastic disease (including asthma and chronic obstructive&#xD;
                  pulmonary disease, treated or not treated),&#xD;
&#xD;
               -  Clinically significant drug allergy or history of atopic allergy (asthma,&#xD;
                  urticaria, eczematous dermatitis)&#xD;
&#xD;
               -  Known hypersensitivity to the study drug or similar drugs&#xD;
&#xD;
               -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
                  distribution, metabolism or excretion of drugs or jeopardize participation in the&#xD;
                  study.&#xD;
&#xD;
               -  Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test&#xD;
                  result.&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.&#xD;
&#xD;
          -  Drug or alcohol abuse within the 12 months prior to dosing&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>safety</keyword>
  <keyword>LAF237</keyword>
  <keyword>vildagliptin</keyword>
  <keyword>Chinese</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

